Allografting Older Patients-Myths and Realities

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 1 SUPPL., 2009, Pages 146-148

  Giralt, Sergio ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; COMORBIDITY; DISEASE FREE SURVIVAL; GERIATRIC CARE; HIGH RISK PATIENT; HUMAN; LEUKEMIA REMISSION; MYELODYSPLASTIC SYNDROME; REDUCED INTENSITY CONDITIONING;

EID: 64749098710     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.12.499     Document Type: Article

References (24)

1. Loberiza F. Report on the state of the art in blood and marrow transplantation. Part 1 of the IBMTR/ABMTR summary slides with guide. IBMTR/ABMTR Newslett 10 (2003) 7-10
2. Frassoni F., Labopin M., Arcese W., et al. The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for AML 1CR is significantly worse after 35 years. Implication for reducing the intensity of the conditioning regimen. Report of the acute leukemia working party of EBMT. Blood 96 (2000) 393a
3. Ringden O., Horowitz M., Gale R., et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 270 (1993) 57-60
4. Gale R., Bortin M., Van Bekkum D., et al. Risk factors for acute graft versus host disease. Br J Haematol 67 (1987) 397-400
5. Horowitz M., Loberiza F., Bredeson C., and Nugent M. Transplant registries: guiding clinical decisions and improving outcomes. Oncology 15 (2001) 649-659
6. Wallen H., Gooley T.G., Deeg H.J., et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 23 (2005) 3439-3446
7. Ditschkowski M., Elmaagacli A.H., Trenschel R., et al. Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients. Clin Transplant 20 (2006) 127-131
8. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft versus-leukemia without myeloablative therapy. Blood 89 (1997) 4531-4536
9. Slavin S., Nagler A., Naparstak E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood 91 (1998) 756-763
10. Khouri I., Keating M.J., Korbling M., et al. Transplant lite: induction of graft vs malignancy using fludarabine based nonablative chemotherapy and allogeneic progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16 (1998) 2817-2824
11. Champlin R., Khouri I., Kornblau J., Molldrem J., and Giralt S. Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft versus malignancy effect. Oncology 13 (1999) 621-626
12. McSweeney P., Niederwieser D., Shizuru J., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
13. Center for International Blood and Marrow Transplant Research. Summary Slides www.cibmtr.org/SERVICES/Observational_Research/Summary_Slides
14. Kiss T.L., Sabry W., Lazarus H.M., and Lipton J.H. Blood and marrow transplantation in elderly acute myeloid leukemia patients-older certainly is not better. Bone Marrow Transplant 40 (2007) 405-415
15. Wong R., Giralt S., Martin T., et al. Reduced intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 102 (2003) 3052-3059
16. de Lima M., Anagnostopoulos A., Mnusell M., et al. Nonablative versus reduced intensity conditioning regimens in the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome: dose is relevant for long term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 865-872
17. Gupta V., Daly A., Lipton J., et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 11 (2005) 764-772
18. Tauro S., Craddock C., Peggs K., et al. Allogeneic stem cell transplantation using a reduced intensity conditioning regimen has the capacity to produce durable remissions and ling term disease free survival in patients with high risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 23 (2005) 9387-9393
19. Hegenbart U., Nierderwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low dose TBI based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 24 (2006) 444-453
20. Popat U., Heslop H.E., Durett A., et al. Outcome of reduced intensity allogeneic hematopoietic stem cell transplantation using antilymphocyte antibodies in patients with high risk acute myeloid leukemia. Bone Marrow Transplant 37 (2006) 547-552
21. Kroger N., Shimoni A., Zabelina T., et al. Reduced toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation in elderly patients with secondary acute myeloid leukemia or myelodysplastic syndrome. Bone Marrow Transplant 37 (2006) 339-344
22. Estey E., de Lima M., Tibes R., et al. Prospective feasibility analysis of reduced intensity conditioning regimens for hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Blood 109 (2007) 1395-1400
23. Sorror M., Storer B., Sandmaier B., et al. Hematopoietic cell transplantation co morbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 112 (2008) 1992-2001
24. Majhail N., Brunstein C., Tomblyn M., et al. Reduced intensity allogeneic transplant in patients older than 55 years of age. Unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant 14 (2008) 282-289